MAYO CLINIC UNVEILS GROUNDBREAKING TOOL THAT REVEALS HIDDEN DNA CHANGES BEHIND CANCER TREATMENT RESISTANCE In a remarkable breakthrough that could reshape how doctors understand and tackle treatment resistant cancers, researchers at the Mayo Clinic have developed a new computational tool capable of detecting hidden genetic changes in tumors -alterations that often escape even the most advanced sequencing technologies. The tool, known as BACDAC, uncovers large scale DNA abnormalities that may play a critical role in how cancers evolve and resist therapy, paving the way for more personalized and effective treatment strategies. Cancer cells often undergo profound structural changes in their DNA -duplications, deletions, or even the doubling of entire genomes. These changes fuel 6 | MedgateTodayGlobal.com I October 2025 tumor growth, drive genetic diversity, and, crucially, enable cancers to adapt to and evade therapies. However, many of these alterations remain undetected in standard genomic testing because they occur at a chromosomal level or are hidden in samples that are not pure enough for current sequencing tools to analyze accurately. BACDAC, developed Middle East & Africa News Update by a team led by Dr. George Vasmatzis at the Mayo Clinic, fills this critical gap. Using advanced algorithms, BACDAC interprets complex whole-genome sequencing data to identify abnormalities such as whole-genome doubling, a hallmark of aggressive and therapy-resistant cancers. The system is designed to detect these variations even in samples with low tumor purity or degraded DNA, a challenge that has long limited the reliability of genomic profiling in clinical settings. The tool has already been successfully applied to over 650 tumors across 12 different cancer types, demonstrating its versatility and robustness across a wide spectrum of malignancies. One of BACDAC’s most striking features is its Constellation Plot, a visual output that transforms intricate genomic data into an intuitive graphical representation. This innovation allows researchers and clinicians to quickly grasp the level of genomic instability within a tumor, helping them anticipate how the disease might behave under different treatment regimens. As Dr. Vasmatzis explains, “For decades, we’ve known that large-scale chromosomal changes shape the course of cancer, but we lacked a scalable, accurate way to map them in real-world clinical samples. BACDAC finally makes that possible.” The implications of this development are far-reaching. By revealing whether a tumor Middle East & Africa has undergone whole-genome doubling or displays chromosomal instability, clinicians can better assess its aggressiveness and potential resistance to therapies such as chemotherapy or targeted drugs. This knowledge could allow oncologists to tailor treatment plans earlier in a patient’s journey, potentially improving outcomes and sparing patients from ineffective therapies. The study also highlights how genomic instability-long recognized as a key driver of cancer evolution-is far more common than previously understood. Through BACDAC’s analysis, researchers found that such large-scale DNA alterations occur across a wide range of tumor types, reinforcing the idea that these changes represent a fundamental mechanism of cancer progression. Importantly, the Mayo Clinic team emphasizes that BACDAC is not just a research instrument but a bridge toward real-world clinical integration. Because the tool works even with low-quality samples, it could be applied to standard biopsies and archived specimens, expanding its use beyond elite research centers. This adaptability makes BACDAC particularly valuable for community hospitals and cancer networks seeking to integrate genomic insights into everyday oncology care. While the tool’s promise is immense, further validation is required before it can be fully adopted in clinical practice. Researchers are now exploring how BACDAC’s findings could inform treatment decisions in prospective studies and whether identifying structural genomic alterations can directly improve patient survival. Cancer experts worldwide have hailed the Mayo Clinic’s innovation as a potential game changer in the field of precision oncology. By uncovering the “hidden architecture” of cancer genomes, BACDAC adds a new layer of understanding to how tumors evolve and adapt -and how medicine can stay one step ahead. In an era where cancer care is increasingly defined by the power of data and molecular insight, the introduction of BACDAC signals a leap forward. It offers clinicians the ability to look beyond mutations and into the deeper structural blueprint of cancer itself -a shift that could redefine how treatment resistance is identified, understood, and ultimately overcome. For decades, we’ve known that large-scale chromosomal changes shape the course of cancer, but we lacked a scalable, accurate way to map them in real-world clinical samples. BACDAC finally makes that possible.